Swiss National Bank
ORMP icon

Swiss National Bank’s Oramed Pharmaceuticals ORMP Stock Holding History

Swiss National Bank’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85,500
Closed -$740K – 2777
2022
Q1 		$740K Buy
85,500
+21,100
+33% +$216K ﹤0.01% 2507
2021
Q4 		$920K Buy
+64,400
New +$1.35M ﹤0.01% 2510

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Swiss National Bank's ORMP Position: Q2 2022 in Review

Swiss National Bank sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 85,500 shares — an estimated $740K sold.

Swiss National Bank first reported a position in ORMP in Q4 2021 and held it in 2 quarters. The position peaked at $920K in Q4 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Swiss National Bank reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 85,500 Oramed Pharmaceuticals shares in Q2 2022, an estimated $740K.
  • Swiss National Bank first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Swiss National Bank's Oramed Pharmaceuticals position peaked at $920K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.